| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |